Penumbra, Inc. (PEN) Stock Price
PENStock
$320.86+26.40%52W
Market Cap$12.64B
P/E71.13x
PEG Ratio3.62
Div yield—
Beta0.69
PEN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-13.31%
Price vs S&P 500 (4W)1.98%
PEG Ratio3.62
VGM Score45.18
P/E Ratio (Annual)71.13x
PEN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.18 | $1.01 | -14.42%(-$0.17) | |
| Q1 2026 | $1.06 | $1.01 | -4.63%(-$0.05) | |
| Q4 2025 | $1.11 | $1.18 | +6.06%(+$0.07) | |
| Q3 2025 | $0.92 | $0.97 | +5.33%(+$0.05) | |
| Q2 2025 | $0.82 | $0.86 | +4.71%(+$0.04) |
PEN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.43
3.43
3.35
3.35
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
PENPenumbra, Inc. | F | C | B | 8.4x | 20.2% | 67.8% | 12.4% | $320.86 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Penumbra, Inc.
US-based Penumbra manufactures minimally invasive medical devices for mechanical removal of blood clots in acute care settings. The company's thrombectomy and embolization devices address stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular conditions, sold primarily to hospitals and physicians.